MIP Technologies AB Presents a New Range of Polymeric Separation Resins for Industrial Use
MIP Technologies (a subsidiary of Biotage AB), a leading global supplier of solutions and technologies for specialty polymeric separation materials, is pleased to present a new range of RENSA industrial resins. The company is now offering industrial resin products together with recently published product- and application notes . These notes describe the materials and physical properties, as well as the performance of the new resins so that customers can select the appropriate resin for their specific separation requirements.
“The food, beverage, pharma, consumer products and life science industries are constantly confronted with new separation challenges as the result of an ever changing regulatory environment and the pressure to achieve a better process economy. In response to this need, MIP Technologies has established a broad range of polymeric materials spanning a wide chemistry landscape that will enable these industries to overcome those separation challenges” says Dr Ecevit Yilmaz, Product Manager — Industrial Resins. “The separation materials can be used by our customers at the pilot and production scale to either extract undesired impurities or to enrich specific target compounds from complex matrices.”
“The area of industrial-scale applications is an important new pillar in the business of Biotage. We will continue to invest into the development of our Industrial Resin portfolio and we will further expand the range of engineered polymeric adsorbents. This will allow us to offer unique and highly selective separation solutions to our wide range of industrial customers” says Dr. Ecevit Yilmaz.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.